Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open, Multi-center Phase I/IIa Clinical Study of RC118 for Injection in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors With Positive Expression of Claudin 18.2

Next Previous
Trial Profile

An Open, Multi-center Phase I/IIa Clinical Study of RC118 for Injection in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors With Positive Expression of Claudin 18.2

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RC 118 (Primary)
  • Indications Cholangiocarcinoma; Gastric cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors RemeGen

Most Recent Events

  • 18 Feb 2024 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
  • 18 Feb 2024 Planned primary completion date changed from 31 Dec 2023 to 30 Sep 2025.
  • 21 Mar 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top